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Abstract
Transmembrane and coiled-coil domains 1 (TMCO1) is a protein of 22 KDa highly 
conserved in amino acid sequence among mammalian species and functions as an 
endoplasmic reticulum (ER) Ca2+load-activated Ca2+channel. Homozygous frameshift 
mutation in TMCO1 causes distinctive craniofacial dysmorphism, skeletal anomalies, 
and mental retardation. However, its physiological functions are largely unknown. In 
this study, we found that TMCO1 was co-localized with microtubules as determined 
by immunohistostaining and a co-sedimentation assay. Interestingly, TMCO1 was 
highly expressed in the invasive front of high grade lung cancer and metastatic cancer 
cells of clinical specimens. To further investigate the biological role of TMCO1 in lung 
cancer, we knocked it down in A549 cells, a human lung adenocarcinoma cell line, by
using shRNA lentiviral particles. Disruption of TMCO1 in the cells resulted in delayed
microtubule polymerization and remarkably increased acetylation of α-tubulin. In 
addition, A549 cells lacking of TMCO1 grew significantly slower than the control 
cells. Taken together, our findings suggest that TMCO1 may be a therapeutic target for 
lung cancer treatment.
